Pharmaceutical companies squeeze sales incentives

Incentives continue to account for about 25% of total compensation. Quota-based bonuses are still the most common, used by 61% of companies with ...

PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023 ...

PBMs' negotiating leverage against pharmaceutical manufacturers has been a key factor inflating the gross-to-net bubble—the ever-growing dollar ...

PBMs and Big Pharma Play Blame Game for Inflated Prescription ...

Pharmacy benefit managers, the powerful prescription drug middlemen who negotiate between pharmaceutical companies and health insurers, took ...

The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending

Key Findings: The wholesaler industry influences the purchase and distribution of prescription drugs in four key areas: setting generic drug ...

PE's Annual Sales and Marketing Employment Survey: The Big ...

... pharmaceutical employers' best intentions to the contrary, sales rep compensation ... Most companies (70 percent) incorporate sales incentives for ...

Insights into why rebates are a target for reducing prices - Milliman

In recent years, pharmaceutical manufacturers have reported actual revenue of 50% to 60% of gross sales due to rebates and discounts. Health ...

FTC report slams pharmacy benefit managers, says firms inflate ...

An ongoing Federal Trade Commission study finds pharmacy benefit managers may have inflated drug costs while squeezing independent ...

Interim FTC Report Finds PBMs Squeeze Independent Pharmacies ...

The PBM industry said the FTC has not been objective, and that efforts to limit PBM negotiating tools would put patients at the mercy of drug ...

Pharmacy Benefit Managers: The Squeeze Is on the Health Care ...

... manufacturers would, necessarily, lose revenue from those potential drug sales. ... rebates with pharma manufacturers that impact patient drug ...

Pharmacy benefit managers are feeling the squeeze - Axios

A robot arm picks up a bottle of pills. ... The specter of banishing back-end drug rebates and more aggressive state action has unnerved pharmacy ...

What to Know About Drug Price Negotiations That Could Save U.S. ...

The ability for the government to haggle over prices is a marked change for pharma companies that have long been able to charge whatever they ...

FTC Accuses Drug Managers Of Squeezing Patients and Pharmacies

Rebates mutually benefit PBMs and the manufacturers of the drugs that are given preferred positioning. Further, rebates can help to mitigate ...

Battling the Big Squeeze - IQVIA

Prevention of unintentional revenue leakage is another area where manufacturers struggle that can be improved. ... Ensuring that rebates are being appropriately ...

FTC Releases Interim Staff Report on Prescription Drug Middlemen

Efforts to limit access to low-cost competitors: PBMs and brand drug manufacturers negotiate prescription drug rebates some of which are ...

Middlemen are often standing between patients and their doctor.

Pharmacy Benefit Managers (PBMs) are “powerful middlemen inflating drug costs and squeezing Main Street pharmacies,” according to a new report from the Federal ...

Economic Factors Squeezing Pharma - CSL UK

While these are the proposed rates, industry bodies and experts predict that the actual rates could be much higher as spend on branded medicines continues to ...

FTC report slams pharmacy benefit managers, says firms inflate ...

An ongoing Federal Trade Commission study finds pharmacy benefit managers may have inflated drug costs while squeezing independent pharmacies, ...

A brief look at current debates about pharmacy benefit managers

Much recent discussion related to PBMs has focused on PBMs' retention of rebates paid by drug manufacturers and use of so-called pharmacy “ ...

Drug supply companies squeezing pharmacies out of existence ...

Drug manufacturers offer rebates to pharmacy benefit managers during negotiations, giving them an incentive to put the costlier drugs higher ...

Big pharma Merck, Bristol Myers, J&J prepare to lose revenue - CNBC

That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats ...